Ibrutinib, an oral small molecule that targets BTK, leads to the inhibition of BTK-specific enzymatic activity. BTK signaling occurs through B-cell antigen receptor and cytokine receptor pathways and affects B-cell trafficking, chemotaxis, and adhesion.11